- Analysis of knowledge from Phase 3 research in uUTI and cUTI to assess the relevance of a optimistic urine tradition in sufferers with no medical signs after being handled for a UTI
- New knowledge on the efficacy of sulopenem in an animal mannequin of anthrax
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical firm centered on growing subsequent era oral and IV antibiotics to deal with infections attributable to multi-drug resistant pathogens in each neighborhood and hospital settings, in the present day introduced that two posters will probably be offered at the Infectious Disease Society of America’s IDWeek 2022.
The hybrid convention will probably be held from October 19-23 at the Walter E. Washington Convention Center in Washington, D.C. Posters will probably be accessible for registrants on the IDWeek Interactive Program and the IDWeek Mobile App beginning on October 19, 8 a.m. ET. Onsite attendees can view posters from Oct. 20-22 from 8 a.m. to 6 p.m.
Data to be offered at IDWeek 2022 embrace:
Presentation Title: Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses within the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection
Poster #: 227
Presenter: Steven Aronin
Time/Location: Thursday, October 20, 12:15 p.m. – 1:30 p.m. in Hall B+C
Presentation Title: Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
Poster #: 1724
Presenter: Sailaja Puttagunta
Time/Location: Saturday, October 22, 12:15 p.m. – 1:30 p.m. in Hall B+C
These Posters will probably be made accessible on the Company’s web site on the “Publications: Posters & Presentations” web page underneath the “Our Science” tab as soon as the convention ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical firm devoted to growing differentiated anti-infectives aimed at combatting the worldwide disaster of multi-drug resistant pathogens to considerably enhance the lives of individuals affected by severe and life-threatening illnesses world wide. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 medical improvement with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro exercise towards all kinds of gram-negative, gram-positive and anaerobic micro organism resistant to different antibiotics. Iterum Therapeutics has acquired Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
[email protected]
